Gilead Sciences, Inc. (GILD) Cash Flow Statement

The negative ratio is driven by a massive non-cash IPR&D impairment, not operational deterioration. Excluding this charge, cash conversion appears healthy, as operating cash flow remained robust. Investors should monitor whether future impairments recur, as they distort the true earnings quality.

Despite the Q2 2026 net loss, FCF generation remains strong, supported by stable HIV sales and disciplined capex. The trajectory shows quarterly FCF ranging from $720M to $4.2B, indicating resilience but also volatility tied to working capital swings. This suggests the core business generates ample cash, though earnings volatility may mislead.

Gilead's asset-light model for small-molecule manufacturing keeps capex minimal, allowing nearly all operating cash flow to convert to FCF. However, the shift toward cell therapies may increase capital intensity over time, potentially pressuring future FCF margins. For now, the low capex/revenue ratio supports robust cash generation.

The large swings likely reflect timing of collections and payables, possibly including 340B program adjustments. While the core business is stable, these swings can obscure underlying cash generation. Investors should focus on trailing twelve-month OCF to smooth out these distortions.

Gilead prioritizes dividends, which are well-covered by operating cash flow, but buybacks are modest relative to peers. The company also deployed cash for acquisitions, with net acquisition outflows in several quarters, indicating a focus on external growth. This balanced approach supports a healthy balance sheet but may limit upside from aggressive repurchases.

The gap is primarily due to large IPR&D impairments and other non-cash items, which depress GAAP earnings but do not affect cash. This suggests the underlying business is far more profitable than reported earnings imply. However, the recurring nature of these charges warrants caution, as they may reflect overpayment for acquisitions.